Tilray Study Maps Cannabinoid Absorption: Oral Formulation Shows Higher Peak Levels Than Spray
LEAMINGTON, Ontario – Tilray Medical, a division of global cannabis leader Tilray Brands, Inc. (NASDAQ: TLRY), has released findings from a significant scientific study shedding light on the pharmacokinetics of two different cannabinoid formulations. The research, a pilot crossover pharmacokinetic study, compared the bioavailability of an oral Tilray THC:CBD extract against an oromucosal spray formulation…